Clinical Trial Update: Ilaris NIS in Korea

View source ↗

Summary

Novartis' canakinumab (Ilaris) is the subject of a Korea-based non-interventional study that is currently recruiting. The study covers hereditary periodic fever…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cryopyrin-associated Periodic Syndromes
• Familial Mediterranean Fever
• Hereditary Periodic Fever Syndromes
• Mevalonate Kinase Deficiency
• Systemic Juvenile Idiopathic Arthritis
• Tnf Receptor-associated Periodic Syndrome

Drugs mentioned

• ILARIS (canakinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Hereditary Periodic Fever Syndromes, Cryopyrin-associated Periodic Syndromes (CAPS) | Status: RECRUITING